- Home
- CRUS vs LEGN Comparison
CRUS vs LEGN Comparison
Compare CRUS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRUS | LEGN |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRUS | LEGN |
|---|---|---|
| Price | $143.57 | $16.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $149.60 | $63.08 |
| AVG Volume (30 Days) | 459.2K | ★ 1.2M |
| Earning Date | 05-05-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | N/A |
| EPS | ★ 6.27 | N/A |
| Revenue | ★ $1,896,077,000.00 | N/A |
| Revenue This Year | $6.27 | $43.65 |
| Revenue Next Year | $1.84 | $32.75 |
| P/E Ratio | $23.74 | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $75.83 | $16.24 |
| 52 Week High | $154.90 | $45.30 |
Technical Indicators
Market Signals| Indicator | CRUS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 37.37 |
| Support Level | $115.31 | $16.24 |
| Resistance Level | $146.81 | $20.39 |
| Average True Range (ATR) | 4.78 | 0.74 |
| MACD | 1.14 | -0.14 |
| Stochastic Oscillator | 54.46 | 0.56 |
Price Performance
Historical ComparisonAbout CRUS Cirrus Logic Inc.
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.